0001193125-19-049296.txt : 20190225 0001193125-19-049296.hdr.sgml : 20190225 20190225112832 ACCESSION NUMBER: 0001193125-19-049296 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190225 DATE AS OF CHANGE: 20190225 EFFECTIVENESS DATE: 20190225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 19628509 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 15-12B 1 d707887d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER

SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION

OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-36562

 

 

LOXO ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

Lilly Corporate Center

Indianapolis, Indiana 46285

Telephone: (317) 276-2000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.0001 par value per share

(Title of each class of securities covered by this Form)

None

(Title of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   ☒
Rule 12g-4(a)(2)   ☐
Rule 12h-3(b)(1)(i)   ☒
Rule 12h-3(b)(1)(ii)   ☐
Rule 15d-6   ☐
Rule 15d-22(b)   ☐

Approximate number of holders of record as of the certification or notice date: One

Pursuant to the requirements of the Securities Exchange Act of 1934, Loxo Oncology, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

    Loxo Oncology, Inc.
Date: February 25, 2019     By:   /s/ Darren J. Carroll
   

Name:

   Darren J. Carroll
   

Title:

   President